Crohn's Disease Treatment in India and UAE | Complete Patient Guide

• ELIGIBLE PATIENTS:

• Adults and adolescents (age ≥ 6 years under pediatric protocols) with confirmed Crohn's disease diagnosis based on endoscopic, histopathological, and cross-sectional imaging criteria

• Patients with moderate-to-severe active disease defined by CDAI ≥ 220, HBI ≥ 8, or elevated fecal calprotectin (> 250 µg/g) with concurrent mucosal inflammation on endoscopy

• Patients failing or intolerant to conventional therapy (corticosteroids, azathioprine, 6-MP, methotrexate) who are candidates for biologic or small-molecule (JAK inhibitor: upadacitinib) induction

• Patients with steroid-dependent or steroid-refractory disease requiring biologic optimization or combination immunosuppression

• Surgical candidates: patients with symptomatic fibrotic strictures (not amenable to endoscopic balloon dilation), internal fistulae (enteroenteric, enterovesical, enterocutaneous), intra-abdominal abscesses following percutaneous drainage and antibiotic stabilization, high-grade dysplasia or malignancy in affected segments, medically refractory disease despite optimized biologic therapy, or growth failure in pediatric patients

• Patients with complex perianal Crohn's disease (complex fistula-in-ano, rectovaginal fistulae) for combined medical (anti-TNF + immunomodulator) and surgical seton/advancement flap management

• REQUIRED PRE-TREATMENT DIAGNOSTICS:

• Ileocolonoscopy with segmental biopsies (histopathological confirmation, CMV exclusion, C. difficile culture)

• MR Enterography (MRE): gold-standard cross-sectional imaging for small bowel disease extent, stricture characterization (inflammatory vs. fibrotic), and fistula mapping

• CT Enterography (CTE): alternative to MRE, particularly in acute presentation or when MRE is not available

• Pelvic MRI: mandatory for perianal Crohn's disease (Parks classification of fistula tract, abscess, sphincter involvement)

• Wireless capsule endoscopy (after excluding strictures by radiological imaging): for isolated small bowel Crohn's beyond the reach of conventional endoscopy

• Fecal calprotectin and fecal lactoferrin (surrogate markers of intestinal inflammation)

• Complete blood count, CRP, ESR, serum albumin, iron studies, vitamin B12, folate, vitamin D, zinc (nutritional assessment panel)

• TB QuantiFERON Gold (IGRA) and chest X-ray: mandatory before initiating anti-TNF or any biologic therapy (latent TB screening)

• Hepatitis B surface antigen, anti-HBc, anti-HBs, Hepatitis C antibody (reactivation risk with immunosuppression)

• Serum infliximab/adalimumab trough levels and anti-drug antibody (ADA) levels: for patients on established biologic therapy (therapeutic drug monitoring)

• TPMT genotyping: before initiating thiopurine therapy

• Stool culture and sensitivity: to exclude infectious colitis complicating IBD

• CONTRAINDICATIONS TO BIOLOGIC THERAPY:

• Active untreated tuberculosis or other serious opportunistic infection

• New York Heart Association Class III–IV congestive cardiac failure (contraindication to anti-TNF agents)

• Active malignancy or lymphoma within 5 years

• Demyelinating disease (relative contraindication to anti-TNF; vedolizumab or ustekinumab preferred)

• Pregnancy (relative; individualized risk-benefit; certolizumab is preferred anti-TNF in pregnancy due to minimal placental transfer)

• CONTRAINDICATIONS TO ELECTIVE SURGERY:

• Active intra-abdominal sepsis not yet controlled (percutaneous drainage first required)

• Severe malnutrition (serum albumin < 25 g/L) requiring pre-operative nutritional rehabilitation (enteral or parenteral nutrition for 4–6 weeks)

• Active high-dose corticosteroid use without tapering (increases anastomotic leak risk; surgery deferred or stoma considered)

MEDICAL (NON-SURGICAL) THERAPIES:

1. Induction and Maintenance with Biologic Agents:

• Anti-TNF Monoclonal Antibodies: Infliximab (IV infusion: 5 mg/kg at weeks 0, 2, 6, then every 8 weeks) and Adalimumab (SC injection: 160/80/40 mg induction, then 40 mg every 2 weeks) are first-line biologics for moderate-to-severe Crohn's. Combination with azathioprine (2.0–2.5 mg/kg/day) reduces immunogenicity and improves sustained remission rates (SONIC trial data: 56.8% corticosteroid-free remission with combination vs. 44.4% infliximab monotherapy at week 26). Therapeutic drug monitoring (TDM) of trough levels (infliximab target: > 3–7 µg/mL in maintenance) is now standard practice at high-quality IBD centers.

• Anti-Integrin Therapy (Vedolizumab): A gut-selective α4β7 integrin antagonist (IV: 300 mg at weeks 0, 2, 6, then every 8 weeks) with a superior safety profile. Preferred for patients with prior malignancy, demyelinating disease, or recurrent infections. Onset is slower (peak response at 14 weeks); optimal for maintenance in biologic-naive moderate disease.

• Anti-IL-12/23 (Ustekinumab): IV weight-based induction dose (~6 mg/kg), followed by SC 90 mg every 8–12 weeks. Highly effective in anti-TNF–experienced patients (UNIFI/IM-UNIFI data). Excellent safety profile; preferred in older patients or those with recurrent infections.

• JAK Inhibitors (Small Molecules): Upadacitinib (Rinvoq, 45 mg once daily induction for 12 weeks, then 30 mg or 15 mg maintenance) received FDA approval for moderate-to-severe Crohn's disease in 2023. Oral administration offers convenience. Monitoring required for lipid profile, CBC, and cardiovascular risk factors. Not recommended in patients > 65 years or with high cardiovascular risk.

2. Immunomodulators:

• Azathioprine (AZA) / 6-Mercaptopurine (6-MP): Used as steroid-sparing agents and in combination with anti-TNF to reduce antibody formation. TPMT genotype and metabolite monitoring (6-TGN levels) guide dosing and toxicity avoidance.

• Methotrexate (MTX): 25 mg IM/SC weekly for induction; 15 mg weekly for maintenance. First choice immunomodulator in men of reproductive age (preferred over thiopurines for teratogenicity avoidance in this context). Effective for luminal Crohn's; folic acid 5 mg weekly co-prescribed.

3. Corticosteroids:

• Used exclusively for short-term induction of remission in acute flares. Budesonide (9 mg/day oral, ileal-release formulation) is preferred for ileocecal disease due to high first-pass metabolism and reduced systemic side effects. Systemic prednisolone/methylprednisolone reserved for severe colonic or systemic disease. Prolonged use is actively avoided.

4. Exclusive Enteral Nutrition (EEN):

• First-line induction therapy for pediatric Crohn's disease (evidence-based, comparable to corticosteroids for luminal remission with superior nutritional benefit). Also used pre-operatively in malnourished adults to improve surgical outcomes.

5. Endoscopic Balloon Dilation (EBD):

• For short (< 5 cm), non-fistulizing, accessible strictures of the terminal ileum or ileocolonic anastomosis. Performed under colonoscopic or device-assisted enteroscopic guidance. Technical success: 86–90%; avoids or delays surgical resection in selected cases.

SURGICAL OPTIONS:

6. Laparoscopic Ileocecal Resection (IIR):

• The most common Crohn's surgery; gold standard for terminal ileal and ileocecal disease not responding to medical therapy or complicated by stricture/abscess. Minimally invasive laparoscopic approach (3–5 port technique) offers shorter hospital stay (5–7 days vs. 10–14 days open), reduced wound complications, faster return of bowel function, and cosmetic benefit. Primary anastomosis (side-to-side functional end-to-end or Kono-S anastomosis) is performed whenever possible. The Kono-S antimesenteric functional end-to-end anastomosis has demonstrated significantly lower endoscopic recurrence rates in randomized trials versus conventional end-to-end anastomosis.

7. Robotic-Assisted Bowel Resection:

• Available at select high-volume centers in India (Medanta, Apollo) and UAE (Cleveland Clinic Abu Dhabi, Mediclinic City Hospital). Robotic platforms (da Vinci Xi) offer superior articulation in the narrow pelvis, particularly advantageous in complex ileocolic resection, segmental colectomy, or proctectomy for rectal Crohn's. Associated with reduced conversion-to-open rates and enhanced precision of mesenteric dissection.

8. Strictureplasty:

• Bowel-conserving procedure for short or long-segment fibrotic small bowel strictures. Heineke-Mikulicz (HM) strictureplasty for strictures < 10 cm; Finney or Jaboulay for 10–25 cm strictures; isoperistaltic side-to-side strictureplasty for longer (> 25 cm) pan-small bowel involvement. Avoids resection and preserves absorptive surface, critical in patients at risk of short bowel syndrome.

9. Perianal Crohn's Surgery:

• Seton placement (loose/cutting seton) for complex transsphincteric fistulae to control sepsis and preserve sphincter function while maintaining medical therapy.

• Ligation of Intersphincteric Fistula Tract (LIFT procedure) for intersphincteric or low transsphincteric fistulae.

• Advancement flap repair (endorectal or dermal) for selected fistulae after achieving quiescent luminal disease.

• Fistula-plug or fibrin glue injection for select patients.

• Video-Assisted Anal Fistula Treatment (VAAFT): minimally invasive endoscopic technique available at advanced centers for direct visualization and closure of the fistula tract without sphincter division.

• Proctectomy with permanent end colostomy: reserved as a last resort for refractory ano-rectal Crohn's with destroyed sphincter complex or intractable pelvic sepsis.

10. Temporary Defunctioning Ileostomy:

• Performed in high-risk anastomotic situations (malnourished patients, high-dose steroids, complex perianal disease, pelvic sepsis) to protect a distal anastomosis and allow staged recovery before restoration of intestinal continuity.

PHASE 1 — PRE-ARRIVAL PREPARATION (4–6 weeks before travel):

• Step 1: Submit medical records to GAF Healthcare (previous endoscopy reports, biopsy histopathology, MR enterography/CT enterography, operative notes if prior surgery, current medication list including biologic therapy details and TDM levels).

• Step 2: GAF Healthcare medical team conducts virtual tele-consultation with the treating gastroenterologist or colorectal surgeon in India or UAE. A personalized treatment plan is formulated (biologic optimization vs. surgical intervention).

• Step 3: Nutritional optimization initiated if pre-operative malnutrition is identified (serum albumin < 30 g/L): enteral nutrition support prescribed for 4–6 weeks; parenteral nutrition reserved for those with obstructing strictures.

• Step 4: Latent TB treatment initiated if QuantiFERON Gold positive (minimum 4 weeks of isoniazid before starting anti-TNF therapy).

• Step 5: Visa arrangement — Indian e-Medical Visa application submitted by GAF Healthcare with hospital invitation letter; UAE patients receive visa-on-arrival or e-Visa arranged by GAF team.

• Step 6: Biologic therapy bridging — for patients mid-course, scheduling of infusion (infliximab) or injection (adalimumab/ustekinumab) timed to coincide with hospital arrival.

PHASE 2 — ARRIVAL AND ADMISSION (Day 0–2):

• Step 7: GAF Healthcare airport pickup with dedicated medical coordinator. Accommodation arranged for patient and attendant in partner hospital guesthouses or nearby hotels.

• Step 8: Day 1 — Full admission workup: repeat CBC, CRP, albumin, LFTs, renal function, coagulation profile. Repeat stool cultures if new symptoms. Infectious disease clearance by in-hospital ID specialist before initiating or resuming immunosuppression.

• Step 9: Day 2 — Multidisciplinary Team (MDT) review: Gastroenterologist, Colorectal Surgeon, Radiologist (cross-sectional imaging review), Nutritionist, and Stoma Therapist (if surgery anticipated). Treatment path confirmed.

PHASE 3A — MEDICAL MANAGEMENT PATHWAY (Days 3–14):

• Step 10: Biologic induction administered (infliximab IV infusion over 2 hours under nursing supervision; premedication with antihistamine and paracetamol; anaphylaxis monitoring for 1 hour post-infusion).

• Step 11: Concurrent nutritional support (elemental or polymeric enteral feeds via nasogastric tube if oral intake inadequate), iron infusion (IV ferric carboxymaltose), and correction of vitamin D and B12 deficiencies.

• Step 12: Day 7–10 — Clinical response assessment (HBI score, CRP trend, patient-reported outcomes). Stool frequency, rectal bleeding, and abdominal pain documented serially.

• Step 13: Day 10–14 — Discharge on maintenance biologic therapy (self-injectable adalimumab or SC ustekinumab with injection training) and oral immunomodulator. Detailed written instructions with emergency contact for GAF Healthcare coordinator.

PHASE 3B — SURGICAL PATHWAY (Days 3–14):

• Step 10: Pre-operative optimization (2–3 days): IV corticosteroid taper, bowel preparation (mechanical prep for colonic surgery; not required for small bowel-only resection), VTE prophylaxis (LMWH), antibiotic prophylaxis (IV cefuroxime + metronidazole at induction).

• Step 11: Enhanced Recovery After Surgery (ERAS) protocol implemented: carbohydrate loading 2 hours pre-op, avoidance of prolonged fasting, epidural or TAP block analgesia, early ambulation.

• Step 12: Day of Surgery — Laparoscopic or robotic-assisted bowel resection (3–4 hours operative time; general anaesthesia; Foley catheter inserted). Intraoperative enteroscopy performed if skip lesion assessment required.

• Step 13: Post-operative Day 1 — ICU or HDU monitoring (fluid balance, anastomotic leak surveillance). Nasogastric tube removed; clear oral fluids commenced. Early mobilisation with physiotherapy.

• Step 14: Post-operative Days 2–4 — Regular diet re-introduced progressively (ERAS protocol). IV analgesia transitioned to oral NSAIDs/paracetamol + low-dose opioid PRN. Stoma output assessment if ileostomy formed.

• Step 15: Post-operative Days 5–7 — Wound assessment, drain removal (if used). Discharge with written ERAS discharge bundle: dietary advice, wound care, stoma care (if applicable), VTE prophylaxis (LMWH for 28 days post-discharge for bowel surgery), and biologic re-introduction plan (typically 2–4 weeks post-surgery after wound healing confirmed).

PHASE 4 — RECOVERY AND FIT-TO-FLY PERIOD:

• Medical Pathway: 2–3 weeks total country stay. Infliximab infusion patients observed for 24 hours post-infusion; discharge and 2-week recovery at local accommodation before flight. Follow-up teleconsult with GAF-linked gastroenterologist arranged at 4 and 12 weeks.

• Surgical Pathway: 4–6 weeks total country stay before international flight. Post-operative review at 2 weeks (wound/stoma check, histopathology results discussion). Fit-to-fly assessment at 4–6 weeks: includes clinical examination, CRP, albumin, and confirmation of no anastomotic complications. DVT prophylaxis on flight (compression stockings + LMWH for journeys > 4 hours).

PHASE 5 — LONG-TERM SURVEILLANCE:

• Endoscopic reassessment at 6–12 months post-surgery (Rutgeerts score for post-operative recurrence at neo-terminal ileum).

• Annual ileocolonoscopy or MRE for monitoring mucosal healing.

• TDM of biologic trough levels at 3 months and annually.

• Colonoscopic dysplasia surveillance from 8 years disease duration (3-yearly in low risk; 1-yearly in high risk with extensive colonic involvement or PSC).